Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

New England Journal of Medicine

Volumn 349, Issue 7, 2003, Pages 658-665

  Heydendael, Vera M R ^a   Spuls, Phyllis I ^a   Opmeer, Brent C ^a   De Borgie, Corianne A J M ^a   Reitsma, Johannes B ^a   Goldschmidt, Wouter F M ^a   Bossuyt, Patrick M M ^a   Bos, Jan D ^a   De Rie, Menno A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; CHRONIC DISEASE; CLASSIFICATION; HOSPITALIZATION; PSORIASIS;

ADULT; CHRONIC DISEASE; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 0042625001     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021359     Document Type: Article

References (20)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
2. Lebwohl M, Ali S. Treatment of psoriasis. 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.
3. Idem. Treatment of psoriasis. 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
4. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28:454-9.
5. Spuls PI, Witkamp L, Bossuyt PMM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997;137:943-9.
6. Spuls PI, Bossuyt PMM, van Everdingen JJE, Witkamp L, Bos JD. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998;134:1591-6.
7. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
8. Weinstein G, Frost P. Methotrexate in psoriasis: a new therapeutic schedule. Arch Dermatol 1971;103:33-8.
9. Roenigk HH Jr, Auerbach P, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
10. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-75.
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
12. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-68.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Ho VC, Griffiths CEM, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol 1999;141:283-91.
15. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-51.
16. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicenter study. Br J Dermatol 1997;136:527-30.
17. Griffiths CEM, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long-term cyclosporin for psoriasis. Br J Dermatol 1989;120:253-60.
18. Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short- and long-term toxicity in 104 patients. Clin Rheumatol 2001;20:406-10.
19. Ortiz Z, Shea B, Saurez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2001;2:CD000951.
20. van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis; a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.